JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barr, V. A.
Right arrow Articles by Taylor, S. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barr, V. A.
Right arrow Articles by Taylor, S. I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 30, 21416-21424, July 23, 1999


Subcellular Localization and Internalization of the Four Human Leptin Receptor Isoforms*

Valarie A. Barr, Kimberly Lane, and Simeon I. TaylorDagger

From the Diabetes Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

There are four known isoforms of the human leptin receptor (HLR) with different C-terminal cytoplasmic domains (designated by the number of unique C-terminal amino acids). In cells expressing HLR-5, -15, or -274, 15-25% of the leptin binding sites were located at the plasma membrane. In contrast, in cells expressing HLR-67, only 5% of the total binding sites were at the plasma membrane. Immunofluorescent microscopy showed that all four isoforms partially co-localized with calnexin and beta -COP, markers of the endoplasmic reticulum and the Golgi, respectively. All isoforms were also detected in an unidentified punctate compartment. All isoforms were internalized via clathrin-mediated endocytosis, but at different rates. After 20 min at 37 °C, 45% of a bound cohort of labeled ligand had been internalized by HLR-15, 30% by HLR-67, 25% by HLR-274, and 15% by HLR-5. Degradation of internalized leptin occurred in lysosomes. Overnight exposure to leptin down-regulated all isoforms, but to a variable extent. HLR-274 displayed the greatest down-regulation and also appeared to reach lysosomes more quickly than the other isoforms. The faster degradation of HLR-274 may help to terminate leptin signaling.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Leptin is a peptide secreted primarily by adipose cells that regulates appetite, energy metabolism, and neuroendocrine function. Leptin acts both centrally, presumably in the hypothalamus, and directly on peripheral tissues (1-3). Leptin binding activates its receptor, a member of the cytokine receptor superfamily, which includes receptors for interleukins, prolactin, growth hormone, and erythropoietin (4, 5). As a result of differential mRNA splicing, there are several isoforms of the leptin receptor with different lengths and C-terminal sequences. The regions that are identical in all the receptor isoforms include the extracellular ligand binding domain, the transmembrane domain, and the first 29 amino acids in the cytoplasmic domain. (4, 6-11).

Some cytokine receptors (e.g. receptors for growth hormone, erythropoietin, and prolactin) form homodimers when activated by ligand, while others form hetero-oligomers (12-14). Recent studies have shown that leptin receptors form homodimers, both in the presence and absence of ligand (15, 16). Each leptin receptor binds one molecule of leptin, resulting in a tetrameric complex composed of two receptors and two leptin molecules. However, activation of the receptor is thought to result from a ligand induced conformational change rather than dimerization of the receptor (15, 17). All the leptin receptor isoforms contain a "box 1" Janus kinase binding site in the cytoplasmic domain. The longest form also contains a "box 2" motif and putative STAT1 binding sites (5, 10, 11, 18) and thus only the long form is able to activate STAT proteins (18-20).

Receptor-mediated endocytosis is a well characterized mechanism for selectively transporting nutrients, hormones, and growth factors into cells. Often receptors are concentrated in clathrin-coated pits and then internalized in clathrin-coated vesicles, although non-clathrin-mediated uptake of receptors also occurs (21, 22). Short amino acid sequences in the cytoplasmic domains of receptors drive receptor internalization. The best known signals are tyrosine-based motifs, although dileucine motifs also promote receptor endocytosis (22). A dileucine sequence is important for the internalization of gp130, a subunit of the IL-6 receptor (23) that is structurally similar to the leptin receptor (4, 5). Leucine pairs are also found in the cytoplasmic domains of the four isoforms of the human leptin receptor, but it is not known if they are important for receptor internalization.

Because little is known about the trafficking of the various isoforms of the human leptin receptor, we inquired whether the different cytoplasmic tails might affect targeting of the receptors to the plasma membrane or affect their endocytosis. Since many interleukin receptors require association with either gp130 or leukemia inhibitory factor receptor for efficient internalization (12-14), we inquired whether leptin receptors would be efficiently endocytosed in the absence of other transfected subunits. Experiments in transiently transfected COS-7 cells showed that there were large intracellular pools of all the isoforms of the leptin receptor and that many of these intracellular receptors resided in the biosynthetic pathway. While all of the isoforms internalized ligand, there were differences in the rates of endocytosis. Furthermore, the longest form of the receptor appeared to be preferentially targeted to lysosomes after internalization.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Unless otherwise noted, all chemicals were reagent grade from Sigma. Restriction enzymes were obtained from Roche Molecular Biochemicals.

Constructs for Leptin Receptors-- Primers (pair 1, TGTGCCTTAGAGGATTATGGGTGTAC and CCACTTAAACCATAGCGAATC; pair 2, GCTGAGAAAATTCCTCAAAGC and GCTAGAGAAGCACTTGGTGAC) were used to obtain two pieces containing the full-length coding sequence for HLR-274 from human brain Marathon cDNA library (CLONTECH Laboratories, Inc., Palo Alto CA) by polymerase chain reaction using an Expand Long Template kit (Roche Molecular Biochemicals). These pieces were assembled in pcr-Script (Stratagene, La Jolla, CA) by restriction digestion and ligation. The DNA sequence of this receptor was determined using ABI PRISM dye terminator cycle sequencing with AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA). Oligonucleotides were synthesized (Integrated DNA Technologies, Inc., Coralville, IA) that contained the unique cytoplasmic sequences of HLR-5 and HLR-15. Primers were used to obtain the C terminus of HLR-67 from a human fetal liver Marathon cDNA library (CLONTECH). Standard molecular biology techniques were used to replace the C terminus of HLR-274 with these sequences. The complete receptor sequences were transferred to the expression vector, pCI-neo (Promega Corp., Madison, WI) by standard methods, and their sequences were confirmed.

Northern Blots-- Strippable riboprobes were made from the pCI-neo HLR-15 and -67 constructs, using Strip-EZ probe kit (Ambion Inc., Austin, TX). A 190-base pair HLR-67 antisense probe was made by cutting the plasmid within the unique cytoplasmic sequence at nucleotide 2884 (numbering according to U664696 cDNA) with NspI and transcribing with T3 RNA polymerase following the instructions from the E-Z probe kit. A shorter 45-base pair HLR-15 antisense probe was made by cutting at nucleotide 2777 (numbering according to U52913 cDNA) with BstNI and transcribing with T3 RNA polymerase. Multiple tissue Northern blots (CLONTECH) were hybridized in QuikHyb (Stratagene) with 1.25 × 106 cpm/ml HLR-67 probe at 68 °C overnight. The blots were washed twice for 15 min in 2× SSC, 0.05 % (w/v) SDS at room temperature, followed by washing four times for 20 min in 0.1× SSC, 0.1% SDS (w/v) at 60 °C. The blots were then exposed to BioMax MS film (Eastman Kodak Co., Rochester, NY) using a TransScreen-HE intensifying screen (Eastman Kodak Co.) for 1 h. Blots were stripped according to Strip-EZ instructions, re-exposed to confirm the removal of the first probe, and reprobed with 0.5 × 106 cpm/ml HLR-15 riboprobe following the same procedure.

Cell Culture and Transfections-- COS-7 cells (ATCC, Fairfax VA) were maintained in Dulbecco's modified Eagle's medium (DMEM) (BioFluids Inc., Rockville, MD) with 10% fetal calf serum at 37 °C in 95% air, 5% CO2. Cells were seeded at 3 × 105 cells/35-mm well 18 h before transfection using liposome-mediated transfection. To transfect cells for the binding studies, we used one of the following two protocols. LipofectAMINE (Life Technologies, Inc.) was used for the binding studies shown in Fig. 3. We followed the manufacturer's instructions using 2 µg of plasmid DNA and 6 µl of LipofectAMINE reagent/well, incubated the cells with this mixture for 5 h, and then replaced the medium. Later experiments were done with cells transfected with LipofectAMINE Plus (Life Technologies, Inc.) using 1 µg of plasmid DNA/6 µl of Plus reagent and 4 µl of LipofectAMINE reagent/well with an incubation time of 4 h.

For immunofluorescence studies, COS-7 cells were transfected using calcium phosphate-mediated transfection (5 Prime-3 Prime Inc., Boulder, CO) following manufacturer's instructions. We used 40 µg of DNA/ml of transfection mixture, 4 h of incubation, and 2 min of glycerol shock.

Binding Assays-- All assays were performed 48 h after transfection. To determine cell surface leptin binding, cells were washed twice with ice-cold PBS and incubated in binding buffer (DMEM, 25 mM HEPES, pH 7.4, 1% (w/v) bovine serum albumin) containing 20,000-30,000 cpm/well of 125I-leptin (NEN Life Science Products) and various concentrations of cold leptin (PreproTech Inc., Rocky Hill, NJ) for 8 h. The medium was removed, and the cells were washed twice with cold PBS, followed by solubilization in 1 ml of 0.4 N NaOH. To determine total leptin binding in extracts, cells were solubilized in binding buffer containing 0.15% (w/v) digitonin, mixed with labeled and cold leptin, and then incubated while rotating at 4 °C overnight. 0.05% (w/v) gamma -globulin and 12.5% (w/v) polyethylene glycol 8000 were added to precipitate receptor-ligand complexes, which were pelleted by centrifugation (16,000 × g for 3 min). The pellets were washed twice in DMEM with 12.5% (w/v) polyethylene glycol 8000 and then counted.

To measure the internalization of a cohort of bound 125I-leptin, cells were washed and incubated with 125I-leptin in binding buffer for 8 h at 4 °C. The media containing 125I-leptin were removed, the cells were washed twice in cold PBS, and 1 ml of fresh binding buffer was added to the cells. After incubation at 37 °C for various times, the media were removed, incubated with 2% (w/v) trichloroacetic acid at 4 °C overnight, and the trichloroacetic acid-insoluble proteins were pelleted by centrifugation (16,000 × g for 10 min). Cell surface leptin was removed by incubating the cells in DMEM, 25 mM HEPES, pH 3.0, twice for 7 min. This removed >95% of the surface 125I-leptin. Finally, the cells were solubilized with 0.4 N NaOH. Continuous uptake of leptin was measured using the same procedure, except the initial binding was only for 4 h and the cells were transferred to 37 °C in the continued presence of ligand. The method of Larkin et al. (24) was modified to measure 125I-leptin internalization in K+-depleted medium. Briefly, transfected cells were hypotonically shocked for 5 min, incubated for 10 min in HEPES-buffered saline, and then pretreated with HEPES-buffered saline supplemented with 1 mM CaCl2 or with 1 mM CaCl2 and 10 mM KCl for 30 min. Continuous internalization of leptin was measured in HEPES buffer with 1% (w/v) dialyzed bovine serum albumin, containing either 1 mM CaCl2 or 1 mM CaCl2 plus 10 mM KCl. The efficacy of inhibition was determined by inhibition of EGF internalization.

Continuous internalization of leptin was also measured in leupeptin-treated cells. Transfected cells were pretreated with 500 µg/ml leupeptin in DMEM for 1 h. After prebinding labeled leptin at 4 °C, continuous uptake of leptin was measured during 2 h at 37 °C as described above, but in the presence of 500 µg/ml leupeptin. The efficacy of the leupeptin treatment was determined by monitoring the inhibition of EGF degradation.

Half-life Determination-- Transfected cells were labeled overnight in DMEM without cysteine or methionine, but supplemented with 0.05 mCi of EasyTag Express Protein Labeling mix/ml medium (NEN Life Science Products). Cells were chased in complete medium, washed, and extracted in lysis buffer (1% (w/v) Triton X-100, 50 mM Tris, pH 7.5, 300 mM NaCl, Complete Protease Inhibitor Mixture (Roche Molecular Biochemicals)). The extracts were cleared by centrifugation (16,000 × g for 30 min), and the leptin receptors were immunoprecipitated overnight at 4 °C with 2 µg/ml goat polyclonal anti-N-terminal antibody (Research Diagnostics, Inc., Flanders, NJ) and 25 µl of Protein G Ultra link beads (Pierce). The beads were washed and made into gel samples, and proteins were separated on 7.5% SDS-PAGE gels. The proteins were transferred to nitrocellulose by standard methods (25), and the 35S-labeled proteins were visualized on BioMax MS film (Eastman Kodak Co.) using a LE TransScreen (Eastman Kodak Co.) to amplify the signal. The same blots were used to determine the amount of protein using a phosphor screen and PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

Immunofluorescence-- Cells were stained for immunofluorescence as described previously (26). Briefly, transfected COS-7 cells were fixed in 2% (v/v) formaldehyde in PBS, stained with goat anti-N-terminal human leptin receptor antibody (12.5 µg/ml) (Research Diagnostics, Inc., Flanders, NJ) in PBS containing 10% (v/v) fetal calf serum and 0.075% (w/v) saponin, and then visualized with lissamine rhodamine-conjugated donkey anti-goat IgG antibody (1:150) (Jackson Immunoresearch Laboratories Inc., West Grove, PA). In the co-localization experiments, the transfected cells were stained with a mixture of the anti-leptin receptor antibody and either rabbit anti-calnexin (1:200) (StressGen Biotechnologies Corp., Victoria, British Columbia, Canada) or rabbit anti-beta -COP (1:500). The anti-beta -COP antiserum was the kind gift of Jennifer Lippincott-Schwartz. The rabbit antibodies were visualized with FITC-conjugated swine anti-rabbit IgG antibody (1:200) (Dako Corp., Carpinteria, CA).

To observe the uptake of anti-receptor antibody, the transfected cells were washed in cold PBS and then incubated with DMEM, 25 mM HEPES (pH 7.5), 0.2% (w/v) bovine serum albumin containing 5 µg of goat anti-N-terminal human leptin receptor antibody at 37 °C. In some experiments, 1 µg/ml leptin or 100 µg/ml human transferrin was included in the incubation. The cells were then fixed and stained with rabbit anti-human transferrin antibody (1:300) (Roche Molecular Biochemicals) and visualized with a mixture of lissamine rhodamine-conjugated donkey anti-goat IgG antibody (1:200) (Jackson Immunoresearch Laboratories) and FITC-conjugated swine anti-rabbit IgG antibody (1:200) (Dako Corp.). To look for transport of the anti-leptin receptor antibody to lysosomes, the transfected cells were pretreated with 500 µg/ml leupeptin, and leupeptin was included in the antibody incubation buffer. After fixation, the cells were stained with mouse anti-LIMP II (CD 63) monoclonal antibody (1:250) (Immunotech, Marseilles France) and visualized with a mixture of lissamine rhodamine-conjugated donkey anti-goat IgG antibody and FITC-conjugated donkey anti-mouse IgG antibody (1:200 each) (Jackson Immunoresearch Laboratories).

Cells were viewed in a Zeiss Axiophot inverted microscope (Carl Zeiss Inc., Thornwood, NY). Images were captured with a PentaMAX camera (Princeton Instruments Inc., Trenton, NJ) and IP Labs software (Scanalytics, Inc., Fairfax, VA) and processed with Adobe Photoshop (Adobe Systems Inc., Mountain View, CA).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We studied the subcellular distribution and the endocytic behavior of the four known isoforms of the human leptin receptor (Fig. 1). Although the first 891 amino acids are identical, the receptors differ after a splice site in the cytoplasmic domain. We have identified each isoform by the number of unique amino acids past this splice point.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Human leptin receptor isoforms. The receptors are differentially spliced at the C terminus resulting in proteins with different cytoplasmic domains. The first 29 amino acids are identical and include a box 1 motif. Each isoform is designated by the number of unique C-terminal amino acids.

HLR-15 and -67 Are Expressed in Tissue-- Previous studies on leptin receptors in mouse have suggested that only the shortest (HLR-5) and longest isoforms (HLR-274) are actually expressed, while the other isoforms were said to be produced at very low levels detectable only by reverse transcription-polymerase chain reaction (27). Therefore, we analyzed Northern blots to determine whether mRNA encoding HLR-15 and HLR-67 is expressed (Fig. 2). HLR-15 mRNA was detected in several tissues including liver, pancreas, spleen, thymus, brain, and fetal lung, while HLR-67 mRNA was found primarily in fetal liver. The restricted expression of HLR-67 suggests that it may have a role in liver development or perhaps in hematopoiesis.


View larger version (111K):
[in this window]
[in a new window]
 
Fig. 2.   Northern blot analysis of the expression of HLR-15 and HLR-67. Northern blots of multiple adult and fetal tissues were probed with isoform specific riboprobes. Both blots were exposed for 1 h using a Kodak TransScreen intensifying screen. A, HLR-15; B, HLR-67.

Leptin Binding in Cells Expressing the Four Isoforms of HLR-- COS-7 cells were transiently transfected with expression vectors encoding each of the HLR isoforms, and the binding of 125I-leptin was studied in both whole cell monolayers and solubilized cell extracts. Steady-state binding was assayed 48 h after transfection. Scatchard plots are shown for representative binding studies for each isoform (Fig. 3, A-D). Similar Kd values were obtained for all the isoforms (average Kd = 0.27 nM ± 0.03); we did not detect any significant differences in the apparent leptin binding affinities between cell surface and solubilized receptors. Four separate transfection experiments were averaged to obtain the total expression of each isoform (Fig. 3E) and the relative surface expression (Fig. 3F). There were 4-fold more total leptin binding sites in cells transfected with HLR-5 than in cells transfected with other receptor isoforms. In agreement with previous studies, HLR-5 had the highest cell surface binding (18, 28), while HLR-274 and HLR-15 had 5-fold fewer surface receptors, and HLR-67 showed very little surface binding of leptin. However, there were large intracellular pools of all the receptor isoforms. About 75% of the total population of HLR-5 and -15, about 85% of -274 was intracellular, and greater than 95% of the HLR-67 were found within the cells. Thus, the increased surface expression of HLR-5 is due primarily to the difference in receptor expression rather than a difference in subcellular distribution.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Distribution of leptin binding sites in COS-7 cells transiently transfected with the four HLR isoforms. COS-7 cells were transiently transfected with expression vectors for HLR-5, HLR-15, HLR-67, or HLR-274. A-D, leptin binding was measured at the cell surface () or in solubilized extracts (open circle ). Each panel shows Scatchard plots of representative binding studies. The inset on panel C shows the cell surface binding on an expanded scale. E and F, data from four experiments were used to estimate the total cellular content of leptin binding sites (E) and the percentage of binding sites at the cell surface (F). Error bars indicate ± S.E.

Half-lives of the Four Isoforms of HLR-- Transfected cells were labeled overnight with Easy Tag Express protein labeling mix and then chased for various times to determine the half-lives of the different isoforms. The amounts of 35S-labeled leptin receptor paralleled the total number of leptin binding sites (Fig. 3), with HLR-5 having the most labeled protein and HLR-67 the least (data not shown). There were no significant differences in the rates at which the different isoforms were degraded; all four isoforms had half-lives of approximately 4 h (ranging from 3.25 h for HLR-274 to 4.5 h for HLR-5). Overnight incubation with leptin did not affect the half-lives of any of the isoforms.

Subcellular Localization of HLR-- The subcellular distributions of the different isoforms were visualized by immunofluorescence microscopy. All isoforms could be detected by antibody labeling at the cell surface in non-permeabilized cells (data not shown). In permeabilized cells, all four isoforms showed similar staining patterns (Fig. 4). Since most cell surface receptors pass through the endoplasmic reticulum (ER) and Golgi during biosynthesis, we inquired whether we could detect leptin receptors in these compartments. In a few cells, almost all the HLR-5 co-localized with calnexin. However, in most transfected cells, HLR-5 partially co-localized with calnexin, a marker of the ER (Fig. 5, A and B) and beta -COP, a marker of Golgi and Golgi-derived vesicles (Fig. 5, C and D). Similar distributions were observed in cells transfected with the other isoforms, although extensive co-localization with calnexin was more common in cells expressing HLR-67 (data not shown). In addition to the receptor visualized in these biosynthetic compartments, most cells contained some bright peripheral punctate staining that did not co-localize with lysosomal markers or with internalized transferrin (data not shown).


View larger version (111K):
[in this window]
[in a new window]
 
Fig. 4.   Immunofluorescent localization of the four HLR isoforms. Transfected COS-7 cells were fixed, permeabilized, and stained with goat anti-leptin receptor antibody, followed by lissamine rhodamine-conjugated anti-goat antibody as described under "Materials and Methods". A, HLR-5-transfected cells; B, HLR-15-transfected cells; C, HLR-67-transfected cells; D, HLR-274-transfected cells.


View larger version (108K):
[in this window]
[in a new window]
 
Fig. 5.   HLR-5 in the biosynthetic pathway. COS-7 cells transiently transfected with HLR-5 were fixed, permeabilized, and stained with a mixture of goat anti-leptin receptor and rabbit anti-calnexin antibodies, followed by lissamine rhodamine-conjugated anti-goat and FITC-conjugated anti-rabbit antibodies as described under "Materials and Methods" (A and B). Alternatively, the transfected cells were stained with a mixture of goat anti-leptin receptor and rabbit anti-beta -COP antibodies, followed by lissamine rhodamine-conjugated anti-goat and FITC-conjugated anti-rabbit antibodies (C and D). A, HLR-5 immunostaining; B, calnexin immunostaining; C, HLR-5 immunostaining; D, beta -COP immunostaining. Arrows show examples of punctate staining that did not co-localize with either calnexin or beta -COP.

Internalization of the Four Isoforms of HLR-- Next, we studied the endocytosis of recombinant leptin receptors. 125I-Leptin was bound to transiently transfected COS-7 cells for 6 h at 4 °C, the free leptin was removed, and the bound label was allowed to internalize for various times at 37 °C. Fig. 6A shows a representative experiment demonstrating the internalization of a cohort of HLR-15 as measured by 125I-leptin internalization. The amount of cell surface label decreased during incubation at 37 °C, while the amount of internalized label increased. Trichloroacetic acid-soluble counts began to appear in the media after about 20 min and then increased during the rest of the time course. Endocytosis of the four different isoforms is compared in Fig. 6 (B-D). After 20 min at 37 °C the sum of internalized leptin plus trichloroacetic acid-soluble cpm accounted for almost 50% of the bound 125I-leptin in HLR-15-transfected cells, 30% in HLR-67-transfected cells, 25% in HLR-274-transfected cells, and 15% in HLR-5-transfected cells. Transiently expressed insulin receptors were endocytosed more rapidly than any of the leptin receptors (the sum of internalized plus degraded insulin was 57% after 20 min at 37 °C), indicating that COS-7 cells are capable of efficient internalization of large numbers of receptors and that the slow internalization of HLR-5 was not due to an intrinsic limitation in the endocytosis pathway. Continuous uptake of labeled leptin was blocked by depleting K+, indicating that all the leptin receptor isoforms were endocytosed via clathrin-coated pits (Fig. 7) (24).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 6.   Leptin internalization by the four receptor isoforms. 125I-Leptin was bound to the transfected cells at 4 °C, and the cells were washed at 4 °C to remove the unbound ligand and then incubated at 37 °C for the indicated time. The medium was removed and treated with trichloroacetic acid. The cells were washed, surface 125I-leptin was removed by acid stripping, and the remaining cells were solubilized in NaOH. Each sample was counted. The x axis shows the percentage of the starting cpm found in each location. Error bars indicate ± S.E. A, internalization of a cohort of 125I-leptin bound to HLR-15 during 90 min at 37 °C; , acid-strippable 125I-leptin bound to the cell surface; , 125I-leptin remaining cell associated after acid stripping (intracellular leptin); , trichloroacetic acid-soluble 125I cpm released into the medium. B-F, comparison of leptin internalization in cells transfected with different receptor isoforms. Cells were transfected with HLR-5 (), HLR-15 (open circle ), HLR-67 (black-down-triangle ), and HLR-274 (down-triangle). B, surface-bound 125I-leptin associated with the four receptor isoforms. C, 125I-leptin remaining cell-associated after acid stripping (intracellular leptin). D, trichloroacetic acid-soluble cpm in the medium. E, trichloroacetic acid-precipitable cpm in the medium. F, sum of intracellular 125I-leptin and trichloroacetic acid-soluble cpm in the medium.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition of leptin internalization by K+ depletion. Transfected cells were allowed to bind 125I-leptin for 4 h at 4 °C and were then incubated in the continued presence of 125I-leptin for 120 min at 37 °C in medium with KCl () or without KCl (open circle ). Cells were treated as described in Fig. 6 and "Materials and Methods." The graphs show the amount of 125I-leptin remaining cell associated after acid stripping (intracellular leptin) plus the trichloroacetic acid-soluble cpm released into the medium. Error bars indicate ± S.E. A, HLR-5-transfected cells; B, HLR-15-transfected cells; C, HLR-67-transfected cells; D, HLR-274-transfected cells.

Further experiments were performed to study multiple rounds of ligand internalization and receptor down-regulation. In continuous uptake experiments, internalized leptin increased during the first hour at 37 °C and then remained constant for the next 4 h (Fig. 8A). After a 30-min lag, trichloroacetic acid-soluble counts accumulated in the media (Fig. 8B). In these experiments, the pool of intact labeled leptin available for binding was depleted by cells expressing HLR-5, making it difficult to see the extent of ligand internalization. Therefore, cells expressing HLR-5 were also studied in the presence of 30 ng of cold leptin. At the 6-h time point, in all cases the soluble cpm accounted for 80% of the sum of internalized plus degraded leptin, indicating that leptin was efficiently degraded after endocytosis by all four receptor isoforms. Leupeptin inhibited leptin and EGF degradation to similar extents (70% inhibition for HLR-5, 62% for HLR-15, 55% for HLR-67, 73% for HLR-274, and 56% for EGF), indicating that lysosomes are the primary site for leptin degradation. At the end of the time course, the sum of internalized plus degraded leptin was greater than the amount of leptin initially bound to the cell surface. For HLR-5 and HLR-274, the final sum was twice the amount initially bound, for HLR-15 the sum was 3 times, and for HLR-67 it was 5 times the amount initially bound. Thus, receptors must continue to appear at the cell surface during incubation at 37 °C. To study down-regulation of the receptors, we examined the effect of longer leptin treatments on the number of cell surface binding sites. Overnight incubation with saturating amounts of leptin resulted in a 50-70% decrease in the amount of 125I-leptin surface binding. The greatest decrease was seen in cells transfected with HLR-274 (Fig. 9).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Continuous uptake of leptin. Cells transfected with the different receptor isoforms were allowed to bind 125I-leptin for 4 h at 4 °C and were then incubated with 125I-leptin for varying times (0-5 h). Cells were treated as described in Fig. 6 and "Materials and Methods." The amounts of 125I-leptin remaining cell-associated after acid stripping (intracellular leptin) and trichloroacetic acid-soluble cpm were compared for the four receptor isoforms. Error bars indicate ± S.E. , HLR-5; open circle , HLR-15; black-square, HLR-5 plus 30 ng of cold leptin; , HLR-67; down-triangle, HLR-274. A, intracellular leptin. B, trichloroacetic acid-soluble cpm.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 9.   Down-regulation of the 4 HLR isoforms. Transfected cells were incubated in complete medium containing various amounts of added leptin for 18 h. The cells were washed, and cell surface leptin binding was measured. The amount of binding is shown in comparison to the amount of binding found in cells that had not been treated with leptin. Error bars indicate ± S.E. , HLR-5; open circle , HLR-15; black-down-triangle , HLR-67; down-triangle, HLR-274.

Antibody Uptake-- To visualize the movement of leptin receptors after internalization from the cell surface, we performed a series of antibody uptake experiments. Antibody was bound to transfected cells at 4 °C and then internalized at 37 °C. The anti-receptor antibody we used was directed against amino acids 32-51 and did not compete with labeled leptin in binding studies (data not shown). Using this approach, we compared the endocytosis pathway of HLR-15 with that taken by transferrin (Fig. 10). As expected, there was some co-localization of internalized antibody with internalized transferrin, as both transferrin and leptin receptors are internalized by clathrin-coated vesicles. However, after only 10 min of uptake, much of the leptin receptor antibody had already separated from structures containing transferrin (Fig. 10, A and B). The punctate staining pattern observed after antibody uptake was similar to the peripheral punctate staining seen in Fig. 4. Furthermore, leptin receptor antibody did not concentrate in the perinuclear compartment containing transferrin (Fig. 10, C and D). The distribution of internalized antibody was not affected by including saturating amounts of leptin during the incubation at 37 °C (data not shown). Similar results were seen with all four isoforms.


View larger version (104K):
[in this window]
[in a new window]
 
Fig. 10.   Visualization of anti-receptor antibody and transferrin uptake in cells transfected with HLR-15. HLR-15-transfected cells were incubated with anti-human leptin receptor antibody and human transferrin for either 10 or 60 min. The cells were then washed, fixed, and stained as described under "Materials and Methods." 10-min uptake at 37 °C: A, internalized anti-HLR antibody; B, internalized transferrin. Arrows indicate representative examples of spots containing both internalized antibody and transferrin. 60-min uptake at 37 °C: C, internalized anti-HLR antibody; D, internalized transferrin. Arrowheads indicate the probable location of the perinuclear recycling endosome where transferrin accumulates.

Anti-leptin receptor antibody was also internalized in the presence of leupeptin to look for the arrival of receptor in lysosomes. After 90 min of antibody uptake in HLR-5-transfected cells, there was little co-localization of a lysosomal marker, LIMP II, with antibodies bound to HLR-5 (Fig. 11, A and B). Similar results were obtained in cells transfected with HLR-15 and HLR-67 (data not shown). However, in cells transfected with HLR-274, there was much more co-localization of the internalized antibody with the lysosomal marker (Fig. 11, D and E). At later times, there was substantial co-localization of anti-leptin receptor antibody with LIMP II in cells expressing any of the four HLR isoforms (data not shown). Thus, it appears that HLR-274 arrives in lysosomes more quickly than other isoforms. Moreover, in cells allowed to internalize a cohort of antibody and then chased overnight in the absence of leupeptin, punctate antibody staining was still visible in cells transfected with HLR-5, HLR-15, and HLR-67 but not in cells transfected with HLR-274. The more rapid degradation of antibody in cells transfected with HLR-274 supports the previous conclusion that HLR-274 is delivered more rapidly to lysosomes.


View larger version (95K):
[in this window]
[in a new window]
 
Fig. 11.   Dual labeling of internalized anti-receptor antibody and LIMP II. Cells were transfected with either HLR-5 or HLR-274, pretreated with leupeptin, and then incubated with anti-HLR antibody for 90 min at 37 °C in the continued presence of leupeptin. The cells were washed, fixed, and stained as described under "Materials and Methods" to detect the internalized antibody and LIMP II (CD 63), a lysosomal protein. Cells transfected with HLR-5: A, internalized anti-HLR antibody; B, LIMP II. Cells transfected with HLR-274: C, internalized anti- HLR antibody; D, LIMP II. Arrows indicate representative examples of spots containing internalized antibody that also stain with anti-LIMP II antibody.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

We studied the trafficking of the four known isoforms of the human leptin receptor. The expression of two isoforms, HLR-5 and HLR-274, is well documented (5, 27, 29-31). We have presented evidence that the two other forms are also expressed in some tissues. The most striking observation is that the steady-state distribution and internalization of all four isoforms were very similar, but with some interesting differences. In comparison to the other isoforms, relatively little HLR-67 was found at the cell surface. In addition, the rates of endocytosis varied, with HLR-15 being internalized the fastest and HLR-5 the slowest. Furthermore, HLR-274 appeared be the most rapidly transported to lysosomes and the most sensitive to down-regulation.

Binding and Signaling-- We found no significant differences in the affinity of leptin binding among the isoforms of the human receptor, just as previous studies found no differences in the mouse isoforms (18). Human leptin levels have been reported to range from 7 to 10 ng/ml in lean humans (0.4-0.6 nM). According to our estimates of the Kd of the leptin receptors (~0.3 nM), at least half of the surface leptin receptors should be occupied normally. Thus, even in the presence of saturating amounts of ligand, the most that leptin receptor occupancy could increase is 2-fold.

Only the longest isoform, HLR-274, is thought to be involved in control of body weight (1, 4, 6, 19). After activation by leptin, the longest mouse receptor isoform can mediate phosphorylation of the receptor as well as Janus kinase-2, insulin receptor substrate-1, and STAT proteins (32, 33). This leads to activation of STAT-dependent gene transcription and increased mitogen-activated protein kinase activity (18, 29, 34). Furthermore, C57Bl/Ks db/db mice, which specifically lack only the long isoform of the leptin receptor, show the same deficiencies as ob/ob mice which produce no leptin (7, 8). This suggests that the long isoform is responsible for mediating most (if not all) biologically relevant actions of leptin. In studies in transfected cells, the long isoform can promote cell proliferation, while both HLR-5 (or the mouse equivalent) and HLR-67 have failed to elicit cellular responses (10, 18, 33). While it has been shown that the shortest mouse isoform can stimulate mitogen-activated protein kinase activity, the physiological relevance of this signal has not yet been elucidated (28, 32). The preferential trafficking of HLR-274 to lysosomes and its enhanced sensitivity to down-regulation may be a way to terminate leptin-induced signals transmitted by this isoform.

Localization-- There were large intracellular pools of all four isoforms of the human leptin receptor. This result is supported by other studies on the localization of endogenous receptor in brain. It has been shown that the endogenous long isoform of the leptin receptor is found predominantly within the cell bodies of rat neurons, not at the cell surface (35, 36). In addition, immunohistochemical localization studies using an antibody that recognizes all leptin receptor isoforms showed intracellular immunoreactivity in brain, including intense intracellular staining of the choroid plexus epithelium, where it is thought that most of the receptor is the shortest isoform (HLR-5) (36, 37). Electron microscopic examination of the distribution of the endogenous long isoform in hypothalamic neurons revealed that most of the intracellular receptors were in the Golgi (38). These results suggest that the localization of transfected leptin receptors is similar to the localization of endogenous leptin receptors. In our studies, we observed leptin receptors in the Golgi, but many transfected receptors were also detected in the ER. Misfolded proteins are often retained in the ER (39-41), but the internal receptors bound leptin with the same affinity as the surface receptors, suggesting that they are not grossly misfolded. ER retention also occurs when one or more subunits are absent from a multisubunit complex (42), but there is no evidence that additional subunits are needed to form either functional leptin receptors or to facilitate the transport of the leptin receptor to the plasma membrane (16). The distribution of leptin receptors is similar to that of related receptors for prolactin and erythropoietin (EPO-R), which are also found in intracellular pools (43, 44). While 25% of HLR-5, HLR-15, and HLR-274 reached the cell surface, 95% of the HLR-67 was retained in the ER. Although the reason for this difference is not known, it is possible that HLR-67 possesses ER retention signals not found in the other isoforms or, alternatively, requires an additional subunit to facilitate exit from the ER. Interestingly, all four isoforms were also seen in an unidentified punctate compartment. Because a similar compartment was seen after endocytosis of anti-receptor antibody, we conclude that this is probably an endosomal compartment.

Half-lives-- The half-lives of all the isoforms were similar and unchanged by exposure to leptin. However, the number of cell surface binding sites was reduced by incubation with excess leptin. This is reminiscent of results reported in studies of the EPO-R, where the bulk of 35S-labeled receptor is a 68-kDa form whose half-life is unaffected by EPO. However, a minor 78-kDa form of the EPO-R appears to be the form found at the cell surface and shows a dramatic decrease in half-life in response to EPO (45). Similarly, it is possible that the half-lives of HLR we measured may represent turnover of the large intracellular pool of receptors and therefore may not reflect turnover of cell surface receptors.

Endocytosis-- All the isoforms of HLR were internalized by a clathrin-mediated mechanism, suggesting that there may a motif in the common cytoplasmic region capable of interacting with AP-2, the plasma membrane adaptor complex (22, 46). However, the slow internalization of HLR- 5 and the differences in the internalization rates suggest that this is a relatively weak signal. HLR-15 and HLR-67 may be aided by additional motifs or interactions with other proteins. HLR-15 possesses a good consensus dileucine motif in its unique cytoplasmic tail, but HLR-67 does not have any obvious endocytic signals. Even these two HLR isoforms were internalized more slowly than other cytokine receptors, including IL-6 receptor hetero-oligomers (23, 47), the growth hormone receptor (48, 49), the prolactin receptor (43), and EPO-R (44, 45). However, all of the leptin receptors were internalized more rapidly than the IL-6 receptor in the absence of functional gp130 (47). Eventually, the receptors arrived in lysosomes and leptin itself was efficiently degraded there. Continuous exposure to ligand caused down-regulation of the leptin receptors, but there were subtle differences among the isoforms. HLR-5 showed the smallest loss of surface binding sites, and HLR-274 showed the largest. Leptin receptors were replenished at the cell surface during incubations at 37 °C. We found large numbers of leptin receptors in intracellular compartments and no visible leptin receptors in the classical recycling pathway defined by transferrin. Thus, it seems likely that most of the leptin receptors appearing at the cell surface came from the intracellular pools rather than endocytosed receptors returning for multiple rounds of ligand uptake. In a similar manner, endocytosed prolactin receptors are replaced with receptors from intracellular stores (43).

Transcytosis of HLR-5-- Leptin transport from blood to brain is specific and saturable (50-52). It has been suggested that HLR-5 may serve as the transcytotic leptin transporter (51, 52). In our study, HLR-5 showed no special intracellular trafficking, although our continuous uptake experiments indicated that there is enough internalization of this abundant isoform to transport substantial quantities of leptin across a cell. Furthermore, the relative insensitivity of this isoform to down-regulation suggests that it could continue to internalize leptin even when serum leptin levels are elevated. However, the degradation of most of the internalized leptin and the delivery of receptor to lysosomes suggests that HLR-5 may not be a transcytotic transporter. When the polymeric IgA receptor, a bona fide transcytotic receptor, is expressed in nonpolarized cells, the ligand is internalized and then re-exocytosed with very little degradation (53). Further evidence against HLR-5 acting as the primary leptin transporter comes from the Koletsky rat, which has a premature stop codon at amino acid 763 in the extracellular domain of the leptin receptor (54). These animals have normal levels of CSF leptin, suggesting that the Koletsky rat does not have a specific transporter defect (52). While further work is needed, these studies do not indicate that the main function of HLR-5 is to transport leptin across the blood brain barrier.

Conclusions-- The differences among the cytoplasmic sequences of the four isoforms of the human leptin receptor do not appear to cause major differences in the localization or trafficking of these receptors. The lack of unique trafficking of HLR-5 makes it unlikely that this isoform functions as a transcytotic transporter. However, its ability to internalize and deliver leptin to lysosomes indicates HLR-5 may be involved in leptin clearance. The relatively rapid degradation of HLR-274 may be a way to terminate leptin signaling. It is interesting that there are large intracellular pools of all of the leptin receptors. We do not know if it is possible to stimulate release of these receptors from their intracellular location to increase the surface expression. Since leptin resistance is generally associated with obesity, a drug that could increase the number of surface HLR-274 might provide an approach to increase leptin sensitivity and treat obesity.

    ACKNOWLEDGEMENT

We are grateful to Dr. Carol Renfrew Haft for critical reading of the manuscript and helpful discussions.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Branch Chief, Diabetes Branch, NIDDK, NIH, Bldg. 10 9S213, 10 Center Dr., Bethesda, MD 20892. Tel.: 301-496-4658; Fax: 301-402-0573; E-mail: sit@box-s.nih.gov.

    ABBREVIATIONS

The abbreviations used are: STAT, signal transducers and activators of transcription; HLR, human leptin receptor; IL, interleukin; PBS, phosphate-buffered saline; ER, endoplasmic reticulum; EGF, epidermal growth factor; LIMP, lysosomal integral membrane protein; EPO, erythropoietin; EPO-R, erythropoietin receptor; PAGE, polyacrylamide gel electrophoresis; FITC, fluorescein isothiocyanate; DMEM, Dulbecco's modified Eagle's medium.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Friedman, J. M., and Halaas, J. L. (1998) Nature 395, 763-770[CrossRef][Medline] [Order article via Infotrieve]
2. Considine, R. V., and Caro, J. F. (1996) Horm. Res. 46, 249-256[Medline] [Order article via Infotrieve]
3. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. M. (1994) Nature 372, 425-432[CrossRef][Medline] [Order article via Infotrieve]
4. Tartaglia, L. A. (1997) J. Biol. Chem. 272, 6093-6096[Free Full Text]
5. Tartaglia, L. A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G. J., Campfield, L. A., Clark, F. T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K. J., Smutko, J. S., Mays, G. G., Woolf, E. A., Monroe, C. A., and Tepper, R. I. (1995) Cell 83, 1263-1271[CrossRef][Medline] [Order article via Infotrieve]
6. Friedman, J. M. (1997) Eur. J. Med. Res. 2, 7-13[Medline] [Order article via Infotrieve]
7. Lee, G. H., Proenca, R., Montez, J. M., Carroll, K. M., Darvishzadeh, J. G., Lee, J. I., and Friedman, J. M. (1996) Nature 379, 632-635[CrossRef][Medline] [Order article via Infotrieve]
8. Chen, H., Charlat, O., Tartaglia, L. A., Woolf, E. A., Weng, X., Ellis, S. J., Lakey, N. D., Culpepper, J., Moore, K. J., Breitbart, R. E., Duyk, G. M., Tepper, R. I., and Morgenstern, J. P. (1996) Cell 84, 491-495[CrossRef][Medline] [Order article via Infotrieve]
9. Chua, S. C., Jr., Chung, W. K., Wu-Peng, X. S., Zhang, Y., Liu, S. M., Tartaglia, L., and Leibel, R. L. (1996) Science 271, 994-996[Abstract]
10. Bennett, B. D., Solar, G. P., Yuan, J. Q., Mathias, J., Thomas, G. R., and Matthews, W. (1996) Curr. Biol. 6, 1170-1180[CrossRef][Medline] [Order article via Infotrieve]
11. Cioffi, J. A., Shafer, A. W., Zupancic, T. J., Smith-Gbur, J., Mikhail, A., Platika, D., and Snodgrass, H. R. (1996) Nat. Med. 2, 585-589[CrossRef][Medline] [Order article via Infotrieve]
12. Finidori, J., and Kelly, P. A. (1995) J. Endocrinol. 147, 11-23[Abstract/Free Full Text]
13. Ihle, J. N. (1995) Nature 377, 591-594[CrossRef][Medline] [Order article via Infotrieve]
14. Kishimoto, T., Taga, T., and Akira, S. (1994) Cell 76, 253-262[CrossRef][Medline] [Order article via Infotrieve]
15. Devos, R., Guisez, Y., Van der Heyden, J., White, D. W., Kalai, M., Fountoulakis, M., and Plaetinck, G. (1997) J. Biol. Chem. 272, 18304-18310[Abstract/Free Full Text]
16. Nakashima, K., Narazaki, M., and Taga, T. (1997) FEBS Lett. 403, 79-82[CrossRef][Medline] [Order article via Infotrieve]
17. Fong, T. M., Huang, R. R., Tota, M. R., Mao, C., Smith, T., Varnerin, J., Karpitskiy, V. V., Krause, J. E., and Van der Ploeg, L. H. (1998) Mol. Pharmacol. 53, 234-240[Abstract/Free Full Text]
18. Baumann, H., Morella, K. K., White, D. W., Dembski, M., Bailon, P. S., Kim, H., Lai, C. F., and Tartaglia, L. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8374-8378[Abstract/Free Full Text]
19. White, D. W., and Tartaglia, L. A. (1996) Cytokine Growth Factor Rev. 7, 303-309[CrossRef][Medline] [Order article via Infotrieve]
20. Ghilardi, N., and Skoda, R. C. (1997) Mol. Endocrinol. 11, 393-399[Abstract/Free Full Text]
21. Schwartz, A. L. (1995) Pediatr. Res. 38, 835-843[Medline] [Order article via Infotrieve]
22. Mukherjee, S., Ghosh, R. N., and Maxfield, F. R. (1997) Physiol. Rev. 77, 759-803[Abstract/Free Full Text]
23. Dittrich, E., Rose-John, S., Gerhartz, C., Mullberg, J., Stoyan, T., Yasukawa, K., Heinrich, P. C., and Graeve, L. (1994) J. Biol. Chem. 269, 19014-19020[Abstract/Free Full Text]
24. Larkin, J. M., Brown, M. S., Goldstein, J. L., and Anderson, R. G. (1983) Cell 33, 273-285[CrossRef][Medline] [Order article via Infotrieve]
25. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354[Abstract/Free Full Text]
26. Haft, C. R., Klausner, R. D., and Taylor, S. I. (1994) J. Biol. Chem. 269, 26286-26294[Abstract/Free Full Text]
27. Fei, H., Okano, H. J., Li, C., Lee, G. H., Zhao, C., Darnell, R., and Friedman, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7001-7005[Abstract/Free Full Text]
28. Murakami, T., Yamashita, T., Iida, M., Kuwajima, M., and Shima, K. (1997) Biochem. Biophys. Res. Commun. 231, 26-29[CrossRef][Medline] [Order article via Infotrieve]
29. Ghilardi, N., Ziegler, S., Wiestner, A., Stoffel, R., Heim, M. H., and Skoda, R. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6231-6235[Abstract/Free Full Text]
30. Luoh, S. M., Di Marco, F., Levin, N., Armanini, M., Xie, M. H., Nelson, C., Bennett, G. L., Williams, M., Spencer, S. A., Gurney, A., and de Sauvage, F. J. (1997) J. Mol. Endocrinol. 18, 77-85[Abstract/Free Full Text]
31. Kielar, D., Clark, J. S., Ciechanowicz, A., Kurzawski, G., Sulikowski, T., and Naruszewicz, M. (1998) Metabolism 47, 844-847[CrossRef][Medline] [Order article via Infotrieve]
32. Bjorbaek, C., Uotani, S., da Silva, B., and Flier, J. S. (1997) J. Biol. Chem. 272, 32686-32695[Abstract/Free Full Text]
33. Takahashi, Y., Okimura, Y., Mizuno, I., Takahashi, T., Kaji, H., Uchiyama, T., Abe, H., and Chihara, K. (1996) Biochem. Biophys. Res. Commun. 228, 859-864[CrossRef][Medline] [Order article via Infotrieve]
34. Vaisse, C., Halaas, J. L., Horvath, C. M., Darnell, J. E., Jr., Stoffel, M., and Friedman, J. M. (1996) Nat. Genet. 14, 95-97[CrossRef][Medline] [Order article via Infotrieve]
35. Baskin, D. G., Schwartz, M. W., Seeley, R. J., Woods, S. C., Porte, D., Jr., Breininger, J. F., Jonak, Z., Schaefer, J., Krouse, M., Burghardt, C., Campfield, L. A., Burn, P., and Kochan, J. P. (1999) J. Histochem. Cytochem. 47, 353-362[Abstract/Free Full Text]
36. Shioda, S., Funahashi, H., Nakajo, S., Yada, T., Maruta, O., and Nakai, Y. (1998) Neurosci. Lett. 243, 41-44[CrossRef][Medline] [Order article via Infotrieve]
37. Couce, M. E., Burguera, B., Parisi, J. E., Jensen, M. D., and Lloyd, R. V. (1997) Neuroendocrinology 66, 145-150[Medline] [Order article via Infotrieve]
38. Diano, S., Kalra, S. P., and Horvath, T. L. (1998) J. Neuroendocrinol. 10, 647-650[CrossRef][Medline] [Order article via Infotrieve]
39. Cresswell, P., and Hughes, E. A. (1997) Curr. Biol. 7, R552-R555[CrossRef][Medline] [Order article via Infotrieve]
40. Klausner, R. D., and Sitia, R. (1990) Cell 62, 611-614[CrossRef][Medline] [Order article via Infotrieve]
41. Lodish, H. F. (1988) J. Biol. Chem. 263, 2107-2110[Free Full Text]
42. Klausner, R. D., Lippincott-Schwartz, J., and Bonifacino, J. S. (1990) Annu. Rev. Cell Biol. 6, 403-431[CrossRef]
43. Genty, N., Paly, J., Edery, M., Kelly, P. A., Djiane, J., and Salesse, R. (1994) Mol. Cell. Endocrinol. 99, 221-228[CrossRef][Medline] [Order article via Infotrieve]
44. Levin, I., Cohen, J., Supino-Rosin, L., Yoshimura, A., Watowich, S. S., and Neumann, D. (1998) FEBS Lett 427, 164-170[CrossRef][Medline] [Order article via Infotrieve]
45. Sawyer, S. T., and Hankins, W. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6849-6853[Abstract/Free Full Text]
46. Hirst, J., and Robinson, M. S. (1998) Biochim. Biophys. Acta 1404, 173-193[Medline] [Order article via Infotrieve]
47. Dittrich, E., Haft, C. R., Muys, L., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 5487-5494[Abstract/Free Full Text]
48. Allevato, G., Billestrup, N., Goujon, L., Galsgaard, E. D., Norstedt, G., Postel-Vinay, M. C., Kelly, P. A., and Nielsen, J. H. (1995) J. Biol. Chem. 270, 17210-17214[Abstract/Free Full Text]
49. Harding, P. A., Wang, X., Okada, S., Chen, W. Y., Wan, W., and Kopchick, J. J. (1996) J. Biol. Chem. 271, 6708-6712[Abstract/Free Full Text]
50. Banks, W. A., Kastin, A. J., Huang, W., Jaspan, J. B., and Maness, L. M. (1996) Peptides 17, 305-311[CrossRef][Medline] [Order article via Infotrieve]
51. Golden, P. L., Maccagnan, T. J., and Pardridge, W. M. (1997) J. Clin. Invest. 99, 14-18[Medline] [Order article via Infotrieve]
52. Wu-Peng, X. S., Chua, S. C., Jr., Okada, N., Liu, S. M., Nicolson, M., and Leibel, R. L. (1997) Diabetes 46, 513-518[Abstract]
53. Deitcher, D. L., Neutra, M. R., and Mostov, K. E. (1986) J. Cell Biol. 102, 911-919[Abstract/Free Full Text]
54. Takaya, K., Ogawa, Y., Hiraoka, J., Hosoda, K., Yamori, Y., Nakao, K., and Koletsky, R. J. (1996) Nat. Genet. 14, 130-131[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit